List
The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.
Searched for: Lung Carcinoma, Non-Small-Cell (NSCLC). 24 results shown below.
FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging
Complete title: Personalized Radiation Therapy through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT)
Principal Investigator: Jing Zeng
Study Number: 9599
Phase: II
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Complete title: Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies with Defined Subsets of Autologous T cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor
Principal Investigator: David Maloney, MD, PhD
Study Number: 9330
Phase: I
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
Complete title: ImmunoRad: Stratified Phase II Trial of Image Guided Hypofractionated Radiotherapy with Concurrent Nelfinavir and Immunotherapy in Advanced Melanoma, Lung Cancer, and Renal Cell Carcinoma
Principal Investigator: Ramesh Rengan
Study Number: 9712
Phase: II
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Complete title: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study).
Principal Investigator: Christina Baik
Study Number: RG1004973
Phase: II/III
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Complete title: A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors
Principal Investigator: Sylvia Lee, MD
Study Number: 10044
Phase: II
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Complete title: A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Principal Investigator: Sylvia Lee, MD
Study Number: 10501
Phase: I
Safety Study of SEA-CD40 in Cancer Patients
Complete title: A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies
Principal Investigator: Andrew Coveler, MD
Study Number: 20150420
Phase: I
Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)
Complete title: METIS: Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)
Principal Investigator: Lynne Taylor, MD
Study Number: 20160306
Phase: III
A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Complete title: A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS
Principal Investigator: Kit Wong
Study Number: 20171486
Phase: I
Phase 2 Study of Poziotinib in Patients With NSCLC With EGFR or HER2 Exon 20 Insertion Mutation
Complete title: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
Principal Investigator: Christina Baik
Study Number: 20172584
Phase: II
Phase 1 Study of the Highly-selective RET Inhibitor BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Complete title: A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-small Cell Lung Cancer (NSCLC) and other Advanced Solid Tumors
Principal Investigator: Christina Baik
Study Number: 20172740
Phase: I/II
A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
Complete title: A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES AND TREATMENT INTENSIFICATION OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN-2 (VBIR-2) (PF-06936308) FOR ADVANCED NON-SMALL CELL LUNG CANCER AND METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Principal Investigator: Nora Disis, MD
Study Number: 20181578
Phase: I
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Complete title: A MULTICENTER, OPEN-LABEL PHASE 1 STUDY
OF U3-1402 IN SUBJECTS WITH METASTATIC OR
UNRESECTABLE EGFR-MUTANT NON-SMALL
CELL LUNG CANCER
Principal Investigator: Christina Baik
Study Number: RG1003503
Phase: I
Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Complete title: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
Principal Investigator: Christina Baik
Study Number: RG1003659
Phase: II
A Phase 2 Study of Tarloxotinib in Patients with Select Gene Alterations and Non-Small Cell Lung Cancer or Other Advanced Solid Tumors
Principal Investigator: Christina Baik
Study Number: RG1004464
Phase: II
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)
Complete title: A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects with Selected Advanced Solid Tumors (DUET-3)
Principal Investigator: Jennifer Specht, MD
Study Number: RG1004763
Phase: I
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD)
Complete title: A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced
Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line
Osimertinib Therapy
Principal Investigator: Christina Baik
Study Number: RG1005292
Phase: II
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous NSCLC
Complete title: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
Principal Investigator: Keith Eaton, MD, PhD
Study Number: RG1005371
Phase: III
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer
Complete title: A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with
BRAFV600E-mutant Non-small Cell Lung Cancer
Principal Investigator: Christina Baik
Study Number: RG1006211
Phase: II
Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer Patients (PACIFIC-4)
Complete title: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4)
Principal Investigator: Jing Zeng
Study Number: RG1006225
Phase: III
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Complete title: A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
Principal Investigator: Daniel Moore
Study Number: RG1006230
Phase: III
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Complete title: An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naive EGFR-mutant Locally Advanced or Metastatic NSCLC
Principal Investigator: Christina Baik
Study Number: RG1006640
Phase: II
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Complete title: A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination with Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients with Advanced Solid Tumors
Principal Investigator: John Liao, MD, PhD
Study Number: RG1007497
Phase: I/II
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Complete title: Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Principal Investigator: Gabriela Chiorean
Study Number: RG1121312
Phase: N/A